Skip to main content
padlock icon - secure page this page is secure

Free Content Estimating the market for tuberculosis drugs in industrialized and developing nations

Download Article:
(PDF 368.5 kb)
BACKGROUND: The successful introduction of new drugs into low- and middle-income countries requires an understanding of the existing market size and market dynamics for the therapeutic area of interest. The drug markets in these countries are, however, less well understood than those in high-income countries.

METHODS: The global market for tuberculosis (TB) drugs was estimated by studying in detail six high-burden countries and four high-income countries, followed by extrapolation. Data were derived from existing pharmaceutical audit databases and interviews with government officials, medical staff and suppliers.

RESULTS: The use of qualitative inputs to inform the collection of quantitative information, notably to identify where the major flows of TB drugs are located, allowed a confident estimate of the global market for first-line TB drugs. Final ranges were US$261–316 million or US$310–418 million, depending on whether case notification rates or incidence were used for extrapolations.

CONCLUSIONS: An estimation of the global TB drug market is made more reliable by a qualitative understanding of TB drug distribution pathways, which differ greatly among countries. The understanding of this structure in key high-burden countries provides the basis for a simpler update of the market estimate in the future.
No Reference information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: global estimate; market size; tuberculosis drugs

Document Type: Regular Paper

Affiliations: 1: Global Alliance for TB Drug Development, New York, New York, USA; and GAVI Alliance, Geneva, Switzerland 2: Global Alliance for TB Drug Development, New York, New York, USA 3: IMS Health Inc, New York, New York, USA; and John F. Kennedy School of Government, Harvard University, Cambridge, Massachusetts, USA 4: IMS Health Inc, New York, New York, USA; and McKinsey & Company, New York, New York, USA 5: IMS Health Inc, New York, New York, USA

Publication date: October 1, 2008

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.

    Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more